Literature DB >> 30804142

Severe Encephalopathy, Lactic Acidosis and Hyperammonaemia With FOLFIRI Plus Aflibercept After Two-stage Hepatectomy: A Case Report.

Yoshihiro Hara1, Yuji Miyamoto1, Yukiharu Hiyoshi1, Masaaki Iwatsuki1, Yoshifumi Baba1, Naoya Yoshida1, Hideo Baba2.   

Abstract

BACKGROUND/AIM: Recent advances in chemotherapy have increased the possibility of conversion hepatectomy for patients with initially unresectable liver metastases. Although long-term chemotherapy and subsequent extensive hepatectomy are becoming more common, the toxicities of such chemotherapies are unclear. PATIENTS AND METHODS: We present a case report of a patient with metastatic colorectal cancer who developed severe encephalopathy with lactic acidosis and hyperammonaemia caused by 5-fluorouracil-based chemotherapy. Administration of vitamin B1 and continuous haemodiafiltration rapidly improved the patient's symptoms.
CONCLUSION: Intensive treatment of metastatic colorectal cancer patients with 5-fluorouracil can induce rare adverse events. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  5-FU; Encephalopathy; hepatectomy; hyperammonaemia; lactic acidosis; metastatic colorectal cancer

Mesh:

Substances:

Year:  2019        PMID: 30804142      PMCID: PMC6506285          DOI: 10.21873/invivo.11511

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  A Rare Case of Severe Lactic Acidosis from 5-Fluorouracil after mFOLFOX6 Treatment in a Patient with Advanced Gastric Cancer.

Authors:  Tae Hoon Lee; Dan Le
Journal:  Case Rep Oncol       Date:  2021-03-22

2.  Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses.

Authors:  Yoshinao Ozaki; Hirotaka Imamaki; Aki Ikeda; Mitsuaki Oura; Shunsaku Nakagawa; Taro Funakoshi; Shigeki Kataoka; Yoshitaka Nishikawa; Takahiro Horimatsu; Atsushi Yonezawa; Takeshi Matsubara; Motoko Yanagita; Manabu Muto; Norihiko Watanabe
Journal:  Cancer Chemother Pharmacol       Date:  2020-10-03       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.